CD19 and B-cell chronic lymphocytic leukemia: Nevertheless, it is important to note that CD19-targeting CAR T cells cannot serve as reasonable comparator here given the artificial nature of the experimental setting and the fact that there is no approved CAR T product for CLL demonstrating clinical efficacy beyond individual patients in early clinical studies33,44,45.